GlassScriptPhysician profile
Amanda Mccann
NPI 1225436488
$6,392.34
in general payments reported to CMS, 2019-2025
30 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,138 · 2022: $1,281 · 2023: $1,161 · 2024: $1,534 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,973.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,706.86 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $555.77 | 2022-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $549.17 | 2021-2024 | Xarelto |
| Amgen INC. | $425.08 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $371.53 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $368.16 | 2024-2025 | Lifevest |
| Irhythm Technologies, INC. | $318.13 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $274.39 | 2021-2025 | |
| Esperion Therapeutics, INC. | $244.79 | 2021-2025 | Nexletol |
| Abbott Laboratories | $230.98 | 2021-2024 | Gallant, Aveir, Merlin@Home |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.52 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $183.81 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $175.56 | 2021-2025 | Farxiga, Andexxa |
| United Therapeutics Corporation | $80.74 | 2021-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $80.55 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $77.27 | 2021-2025 | Uptravi |
| Alnylam Pharmaceuticals INC. | $72.38 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $72.26 | 2024 | Arcalyst |
| Nuwellis, INC. | $65.19 | 2021 | |
| Edwards Lifesciences Corporation | $52.23 | 2021-2024 | |
| Chiesi USA, INC. | $46.23 | 2021-2023 | Cleviprex, Kengreal |
| E.R. Squibb & Sons, L.L.C. | $39.82 | 2024-2025 | Camzyos, Eliquis |
| Daiichi Sankyo INC. | $36.86 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $34.47 | 2023 | Inpefa |
| Boston Scientific Corporation | $32.20 | 2022 | |
| Amarin Pharma, INC. | $23.14 | 2022 | |
| Abiomed | $20.45 | 2022 | |
| Medtronic, INC. | $14.92 | 2021 | |
| Scpharmaceuticals INC. | $14.84 | 2023 | |
| Philips North America LLC | $14.04 | 2024 | (Cm9) Amb Mon & Diag Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.